News Detail

Bioretec names Conan Cavanagh as R&D chief, executive team member

PUBT · 06/17 13:01

Listen to the news

Bioretec names Conan Cavanagh as R&D chief, executive team member

Bioretec appointed Conan Cavanagh as chief R&D officer, effective Sept. 1, 2026.
Cavanagh joins the management team, reporting to CEO Sarah van Hellenberg Hubar-Fisher.
He is currently COO and head of R&D at HidraMed Solutions.
Previous roles include engineering director at Smith & Nephew, overseeing orthopedic and sports medicine development and commercialization.
Mandate covers R&D strategy, portfolio leadership, product development execution, clinical evidence, readiness, long-term growth support.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioretec Oyj published the original content used to generate this news brief via Cision (Ref. ID: 202606170900BITN____UKPR__FI_20260617-BIT-8995-0) on June 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.

What's Trending

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.